Factors / Patients who received rituximab
(n=663) / Patients who did not receive rituximab
(n=1371) / P-Value
Median age (Range)
Gender (M/F)
Stage
-Stage I/II
-Stage III/IV
B symptoms
HIV infection (Positive anti-HIV)
Elevated LDH
ECOG Performance status 2
Extranodal involvement > 1 site
Site of extranodal involvement
-Gonad
-Breast
-Bone marrow
-Kidney/Adrenal gland
High Intermediate/High risk IPI
High CNS-IPI risk
Intrathecal CNS chemoprophylaxis
Response to treatment
-CR
-Less than CR or unknown / 60 (15-89)
313/350
257 (38.8%)
406 (61.2%)
301 (45.4%)
54 (8.3%)
394 (59.4%)
132 (19.9%)
92 (13.9%)
10 (1.5%)
25 (3.8%)
150 (22.6%)
11 (1.7%)
227 (34.2%)
85 (12.8%)
78 (11.8%)
437 (65.9%)
226 (34.1%) / 56 (15-88)
625/746
538 (39.2%)
833 (60.8%)
694 (50.6%)
194 (14.2%)
841 (61.3%)
318 (23.2%)
239 (17.4%)
30 (2.2%)
32 (2.3%)
372 (27.1%)
22 (1.6%)
485 (35.4%)
196 (14.3%)
134 (9.8%)
680 (49.6%)
691 (50.4%) / 0.01
0.49
0.84
0.03
0.01
0.41
0.10
0.05
0.30
0.07
0.03
0.93
0.50
0.29
0.17
<0.001

Supplementary Table 1:Baseline characteristics and responses of DLBCL stratified whether receiving rituximab with induction treatment

Supplementary Table 2: First line inductionchemotherapy regimens used in the cohort

Chemotherapy Regimens / n=2034 (%)
  • CHOP-21
  • CHOP-14
  • CHOP-28
  • CHOEP
  • DA-EPOCH
  • CHOP alternated with ESHAP
  • CEOP
  • CNOP
  • HyperCVAD
  • CODOX-M
/ 1522 (74.8%)
40 (2.0%)
379 (18.6%)
23 (1.1%)
28 (1.4%)
15 (0.7%)
5 (0.2%)
6 (0.3%)
13 (0.6%)
3 (0.1%)

Supplementary Table 3:Number of cycles of first line induction treatment

Number of Cycles / n=2034 (%)
  • 1-3
  • 4-5
  • 6-8
/ 147 (7.2%)
107 (5.3%)
1780 (87.5%)

Supplementary Table 4: CNS directedtreatment of secondary CNS relapse*

Treatment / n=61 (%)
  • Intrathecal chemotherapy
  • Systemic chemotherapy containing high dose methotrexate or cytarabine
  • Radiotherapy
  • No CNS directed treatment
/ 22 (36.1%)
6 (9.8%)
19 (31.1%)
29 (47.5%)

*11 patients had combined modalities of CNS directed treatment

Supplementary Figure 1: 1A: Kaplan Meier PFS of all patients. 1B: Kaplan Meier OS of all patients. 1C: Cumulative incidence of relapse (all relapse)